<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T03:31:22Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/13298" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/13298</identifier><datestamp>2025-10-24T10:36:26Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Café-Au-Lait Macules in Neurofibromatosis Type 1: Birthmark or Biomarker?</dc:title>
   <dc:creator>Santangelo, Andrea</dc:creator>
   <dc:creator>Chelleri, Cristina</dc:creator>
   <dc:creator>Pasquinucci, Mattia</dc:creator>
   <dc:creator>Cappozzo, Francesca</dc:creator>
   <dc:creator>Striano, Pasquale</dc:creator>
   <dc:creator>Tomasino, Marco</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Santangelo A, Striano P] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.  [Chelleri C, Pasquinucci M, Cappozzo F] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.  [Tomasino M] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>Marcadors bioquímics</dc:subject>
   <dc:subject>Neurofibromatosi - Diagnòstic</dc:subject>
   <dc:subject>Trastorns de la pigmentació</dc:subject>
   <dc:subject>Neurofibromatosi - Aspectes genètics</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Nerve Tissue::Nerve Sheath Neoplasms::Neurofibroma::Neurofibromatoses::Neurofibromatosis 1</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms::Neoplastic Syndromes, Hereditary::Neurofibromatoses::Neurofibromatosis 1</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::Other subheadings::/genetics</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis</dc:subject>
   <dc:subject>CHEMICALS AND DRUGS::Biological Factors::Biomarkers</dc:subject>
   <dc:subject>ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::trastornos de la pigmentación::manchas café con leche</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias::síndromes neoplásicos hereditarios::neurofibromatosis::neurofibromatosis 1</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/genética</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz</dc:subject>
   <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores</dc:subject>
   <dc:description>Café-au-lait macules; Early diagnosis; Neurofibromatosis</dc:description>
   <dc:description>Máculas café con leche; Diagnóstico precoz; Neurofibromatosis</dc:description>
   <dc:description>Màcules cafè amb llet; Diagnòstic precoç; Neurofibromatosi</dc:description>
   <dc:description>Background: Neurofibromatosis type 1 (NF1) is a rare multisystem disorder characterized by variable expressivity and increased tumor risk. Café-au-lait macules (CALMs) are a hallmark of the disease, often representing one of the earliest clinical manifestations and allowing a clinical NF1 diagnosis if six or more are present. In this study, we aimed to investigate the prognostic value of CALMs at birth in NF1 patients. Methods: We conducted a retrospective study in patients aged ≥ 4 years presenting with CALMs at our Institution between 2020 and 2021, with a minimum follow-up of four years. We retrospectively collected data on CALMs at birth and other clinical manifestations associated with NF1. Results: Among 208 patients evaluated, including 147 with a confirmed diagnosis of NF1, 110 did not show CALMs at birth, and 98 had at least one. The absence of CALMs at birth did not correlate with a lower likelihood of NF1. In contrast, the CALM number at birth directly correlated with the likelihood of NF1, up to 95% in patients with ≥5 macules. Additionally, a higher number of CALMs correlated with a greater prevalence of plexiform neurofibromas (p &lt; 0.001). Conclusions: Our findings suggest that a higher number of CALMs may indicate a more severe form of NF1, with an increased risk of plexiform neurofibromas. These results emphasize the importance of a comprehensive evaluation of patients with CALMs, especially in case of multiple lesions, aiming at implementing early NF1 diagnosis, follow-up strategies, and overall patient management.</dc:description>
   <dc:description>This research was supported by PNRR-MUR-M4C2 PE0000006 Research Program “MNESYS”—A multiscale integrated approach to the study of the nervous system in health and disease.</dc:description>
   <dc:date>2025-06-17T08:28:59Z</dc:date>
   <dc:date>2025-06-17T08:28:59Z</dc:date>
   <dc:date>2025-05</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Santangelo A, Chelleri C, Tomasino M, Pasquinucci M, Cappozzo F, Striano P, et al. Café-Au-Lait Macules in Neurofibromatosis Type 1: Birthmark or Biomarker? Cancers (Basel). 2025 May;17(9):1490.</dc:identifier>
   <dc:identifier>2072-6694</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/13298</dc:identifier>
   <dc:identifier>10.3390/cancers17091490</dc:identifier>
   <dc:identifier>40361417</dc:identifier>
   <dc:identifier>001486649000001</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/13298</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Cancers;17(9)</dc:relation>
   <dc:relation>https://doi.org/10.3390/cancers17091490</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>MDPI</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>